It is stated by Hogarth and Hall(29) that the BCL2 expression levels can’t be useful inthe prognosis of the ALL patients, but obviously, thedownregulation of this gene, which might be happeningvia the promoter methylation processes, can be a valuablefactor in tumor regression. The gene discussed is BCL2; the disease is neoplasm.